Panuveitis Treatment Industry Forecasted for Rapid Expansion, Reaching $6.88 Billion by 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Current Market Size and Growth Rate of the Paraganglioma Market?
The panuveitis treatment market size has grown strongly in recent years. It will grow from $4.35 billion in 2025 to $4.74 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited access to ophthalmology specialists, dependence on corticosteroid therapies, lack of advanced diagnostic tools, low awareness of panuveitis complications, fragmented treatment infrastructure.

The panuveitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in biologic and immunotherapy drugs, increasing prevalence of autoimmune and infectious eye disorders, growth of teleophthalmology and digital monitoring, rising investments in ai-based diagnostics, expansion of hospital and specialty clinic distribution channels. Major trends in the forecast period include rising adoption of biologic and targeted therapies, integration of teleophthalmology and remote monitoring, ai-assisted diagnostic tools for uveitis, growth of personalized eye care solutions, expansion of specialized ophthalmology centers.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13157&type=smp

What Are the Major Drivers Influencing the Panuveitis Treatment Market?
Rising prevalence of autoimmune disorders is expected to propel the growth of the panuveitis treatment market going forward. Autoimmune disorders are on the rise due to a combination of genetic predispositions, environmental factors like pollution and dietary changes, and increased exposure to certain infections and stressors that may trigger immune system dysregulation. Autoimmune disorders contribute to advancements in panuveitis treatment by driving research into immune system modulation, as many panuveitis cases are related to autoimmune activity. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect 10% of the world's population, with 13% of women and 7% of males affected. Therefore, rising prevalence of autoimmune disorders is driving the growth of the panuveitis treatment market.

What Segment Categories Define the Panuveitis Treatment Market Structure?
The panuveitis treatment market covered in this report is segmented –

1) By Drug Class: Anti-Inflammatory, Antimicrobial Drugs, Immunotherapy And Targeted Therapies
2) By Route Of Administration: Oral, Topical
3) By End Users: Hospitals, Home Care, Specialty Clinics, Other End Users

Subsegments:
1) By Anti-Inflammatory: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Antimicrobial Drugs: Antibiotics, Antifungal Agents, Antiviral Medications
3) By Immunotherapy And Targeted Therapies: Biologic Agents, Janus Kinase (JAK) Inhibitors, Cytokine Modulators

Which Emerging Trends Are Driving the Panuveitis Treatment Market?
Major companies operating in the panuveitis treatment market are focusing on developing innovative products, such as oral dual TYK2/JAK1 inhibitors, to gain a competitive advantage. This class of small-molecule immunomodulator suppresses multiple pro-inflammatory cytokine pathways, reducing intraocular inflammation while offering the convenience of oral dosing. For instance, in April 2024, Priovant Therapeutics, a US-based biotech, announced that its oral agent brepocitinib, which inhibits TYK2 and JAK1, showed strong efficacy in a mid-stage clinical study in non-infectious uveitis, reducing macular edema in several patients. The key advantages include broad cytokine inhibition, daily oral administration, and reduced reliance on intravitreal injections. However, the risks include potential systemic immunosuppression and off-target effects, which require careful long-term monitoring.

Which Are the Top Companies in the Panuveitis Treatment Market?
Major companies operating in the panuveitis treatment market are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Allergan Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., EyeGate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Graybug Vision Inc., Aciont Inc., Clearside Biomedical Inc., Aldeyra Therapeutics Inc., UCB S.A., Amgen Inc., Sanofi S.A., Galapagos NV, Kiora Pharmaceuticals Inc., ONL Therapeutics, Eyevensys, Nicox S.A., Abbott Laboratories

Get the full panuveitis treatment market report here:
https://www.thebusinessresearchcompany.com/report/panuveitis-treatment-global-market-report

How does the Panuveitis Treatment Market perform across different regions?
North America was the largest region in the panuveitis treatment market in 2025. The regions covered in the panuveitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company